Patients taking a widely used blood pressure drug are being advised to verify their medication after a batch was recalled due to incorrect dosage information printed on the packaging. According to the Medicines and Healthcare Products Regulatory Agency (MHRA), some packs of lercanidipine, manufactured by Recordati Pharmaceuticals, have been wrongly labelled as containing 10mg tablets, when in fact they contain 20mg tablets.Over 7000 Packs Are Subject To RecallMore than 7,700 packs already distributed are now subject to the recall, the MHRA has confirmed. Patients who may have the mislabelled medication are being urged to contact their GP, pharmacist, or call NHS 111 for advice. The NHS warns that consuming an excessive dose of lercanidipine can lead to symptoms such as dizziness and drowsiness. The MHRA issued the alert on Thursday after being informed by the Italian pharmaceutical company Recordati that the error was confined to a single batch of lercanidipine, which was initially distributed on April 10. The recalled packs carry the batch number MD4L07 and are marked with an expiry date of January 2028.Although the front of the affected packs displays the incorrect strength, the correct 20mg dose is printed on the blister strips inside and on the side of some of the boxes. The MHRA advises patients who have been prescribed the 20mg dose to check the blister packaging to ensure they have received the correct medication. However, those prescribed 10mg tablets should seek immediate medical attention if they have this batch.As a temporary measure, the MHRA suggests that patients who cannot reach a healthcare provider may take half of a 20mg tablet until they receive professional guidance. Dr Alison Cave, the MHRA’s chief safety officer, stated: "Healthcare professionals such as pharmacists are also being asked to stop supplying medicine from the affected batch and to return it to the supplier." She encouraged anyone experiencing suspected side effects to report them through the MHRA’s Yellow Card scheme.In a statement to the BBC, a spokesperson for Recordati said the company is "working proactively" with the MHRA and will contact all customers who might have received the affected batch. “We are investigating the root cause and continue to work with our partners to isolate the issue and minimise disruption to our patients. Patient safety remains our top priority,” the spokesperson added.What Do We Know About Lercanidipine?Lercanidipine is used in the treatment of Angina (heart-related chest pain), Hypertension (high blood pressure), Arrhythmia, hypertensive emergency, subarachnoid haemorrhage and anal fissure. According to the NHS, it is one of the four types of blood pressure medicines sold across the UK. These pills are a calcium channel blocker. That means it regulates blood pressure by relaxing blood vessels and reducing pressure on them, thereby making it easier for the heart to pump more blood throughout the body. In this way, it normalises the blood pressure in patients with high blood pressure. ALSO READ: RFK Jr.'s Autism Controversial Comments Face Backlash From Parents And Medical Experts